Tugrul Purnak1, Cumali Efe2, Taylan Kav1, Staffan Wahlin3, Ersan Ozaslan4. 1. Department of Gastroenterology, Hacettepe University, Ankara, Turkey. 2. Department of Gastroenterology, Hacettepe University, Ankara, Turkey. drcumi21@hotmail.com. 3. Hepatology Division, Centre for Digestive Disease, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden. 4. Department of Gastroenterology, Numune Research and Education Hospital, Ankara, Turkey.
Abstract
BACKGROUND: Beyond available guidelines, therapy of autoimmune hepatitis (AIH) shows wide variation among physicians. We compared two regimens for treatment naive AIH: one recommended protocol with an initial prednisolone dose of 30 mg/day and our own 40 mg/day prednisolone with a slow dose tapering protocol. We analyzed the safety, response rates, and outcomes for two groups of treated patients. PATIENTS AND METHODS: We retrospectively evaluated data of 71 AIH patients including, group I (n = 32, prednisone 30 mg/day) and group II (n = 39, prednisone 40 mg/day). All patients also received azathioprine. RESULTS: The frequency of complete biochemical response was significantly higher in group II than in group I (69.2 vs. 43.8%, p = 0.031) after 3 months of therapy, but not after 6 and 12 months (79.5 vs. 59.4%, p = 0.065 and 89.5 vs. 80.6%, p = 0.30). In patients with severe interface hepatitis, the complete response rates were significantly higher in group II than in group I after 3 (63.6 vs. 23.1%, p = 0.02) and 6 months (72.7 vs. 38.5%, p = 0.046), but not after 12 months of therapy (86.4 vs. 69.2%, p = 0.221). Relapses were observed in 50% of group I and in 35.9% of group II during maintenance therapy (p = 0.23). Overall survival was significantly better in group II than in group I (100 vs. 87.5%, log-rank, p = 0.048). No severe steroid-related side effects were observed in either group. CONCLUSIONS: Our real-world experience suggests that an initial prednisolone dose of 40 mg/day with a slower tapering protocol induces earlier biochemical response, tends to result in less relapses during maintenance, and is associated with a better disease outcome.
BACKGROUND: Beyond available guidelines, therapy of autoimmune hepatitis (AIH) shows wide variation among physicians. We compared two regimens for treatment naive AIH: one recommended protocol with an initial prednisolone dose of 30 mg/day and our own 40 mg/day prednisolone with a slow dose tapering protocol. We analyzed the safety, response rates, and outcomes for two groups of treated patients. PATIENTS AND METHODS: We retrospectively evaluated data of 71 AIH patients including, group I (n = 32, prednisone 30 mg/day) and group II (n = 39, prednisone 40 mg/day). All patients also received azathioprine. RESULTS: The frequency of complete biochemical response was significantly higher in group II than in group I (69.2 vs. 43.8%, p = 0.031) after 3 months of therapy, but not after 6 and 12 months (79.5 vs. 59.4%, p = 0.065 and 89.5 vs. 80.6%, p = 0.30). In patients with severe interface hepatitis, the complete response rates were significantly higher in group II than in group I after 3 (63.6 vs. 23.1%, p = 0.02) and 6 months (72.7 vs. 38.5%, p = 0.046), but not after 12 months of therapy (86.4 vs. 69.2%, p = 0.221). Relapses were observed in 50% of group I and in 35.9% of group II during maintenance therapy (p = 0.23). Overall survival was significantly better in group II than in group I (100 vs. 87.5%, log-rank, p = 0.048). No severe steroid-related side effects were observed in either group. CONCLUSIONS: Our real-world experience suggests that an initial prednisolone dose of 40 mg/day with a slower tapering protocol induces earlier biochemical response, tends to result in less relapses during maintenance, and is associated with a better disease outcome.
Authors: Michael P Manns; Albert J Czaja; James D Gorham; Edward L Krawitt; Giorgina Mieli-Vergani; Diego Vergani; John M Vierling Journal: Hepatology Date: 2010-06 Impact factor: 17.425
Authors: R Todd Stravitz; Jay H Lefkowitch; Robert J Fontana; M Eric Gershwin; Patrick S C Leung; Richard K Sterling; Michael P Manns; Gary L Norman; William M Lee Journal: Hepatology Date: 2011-01-05 Impact factor: 17.425
Authors: Nicole M F van Gerven; Bart J Verwer; Birgit I Witte; Bart van Hoek; Minneke J Coenraad; Karel J van Erpecum; Ulrich Beuers; Henk R van Buuren; Rob A de Man; Joost P H Drenth; Jannie W den Ouden; Robert C Verdonk; Ger H Koek; Johannes T Brouwer; Maureen M J Guichelaar; Chris J J Mulder; Karin M J van Nieuwkerk; Gerd Bouma Journal: J Hepatol Date: 2012-09-16 Impact factor: 25.083
Authors: Cumali Efe; Hannes Hagström; Henriette Ytting; Rahima A Bhanji; Niklas F Müller; Qixia Wang; Tugrul Purnak; Luigi Muratori; Mårten Werner; Hanns-Ulrich Marschall; Paolo Muratori; Fulya Gunşar; Daniel Klintman; Albert Parés; Alexandra Heurgué-Berlot; Thomas D Schiano; Mustafa Cengiz; Michele May-Sien Tana; Xiong Ma; Aldo J Montano-Loza; Thomas Berg; Sumita Verma; Fin Stolze Larsen; Ersan Ozaslan; Michael A Heneghan; Eric M Yoshida; Staffan Wahlin Journal: Clin Gastroenterol Hepatol Date: 2017-06-08 Impact factor: 11.382
Authors: George N Dalekos; Pinelopi Arvaniti; Nikolaos K Gatselis; Anna Samakidou; Stella Gabeta; Eirini Rigopoulou; George K Koukoulis; Kalliopi Zachou Journal: Front Immunol Date: 2022-01-11 Impact factor: 7.561